300723.SZ
一品红
SZSE · Healthcare · C 制造业 · CN
CNY 34.61
−5.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 940.8M | 932.3M | 1.5B | 2.5B | 2.3B |
| Cost of Revenue | 389.7M | 405.8M | 560.5M | 474.6M | 300.2M |
| Gross Profit | 551.1M | 526.5M | 889.7M | 2.0B | 2.0B |
| Operating Expenses | |||||
| R&D Expense | 158.7M | 157.3M | 312.1M | 301.4M | 189.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 356.7M | 348.2M | 325.6M | 329.4M | 214.7M |
| Selling & Marketing Expense | 327.3M | 322.0M | 505.6M | 1.1B | 1.2B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 912.8M | 897.9M | 1.2B | 1.8B | 1.7B |
| Cost and Expenses | 1.3B | 1.3B | 1.8B | 2.3B | 2.0B |
| Operating Income (EBIT) | 224.9M | (357.5M) | (370.7M) | 213.9M | 282.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 163.1M | (369.4M) | (645.7M) | 244.2M | 326.4M |
| Income Tax Expense | (29.6M) | (23.0M) | (79.0M) | 92.4M | 64.3M |
| Bottom Line | |||||
| Net Income | 200.0M | (337.8M) | (540.0M) | 184.6M | 290.7M |
| Earnings from Cont. Ops | 192.7M | (346.5M) | (566.7M) | 151.8M | 262.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 200.0M | (337.8M) | (540.0M) | 184.6M | 290.7M |
| Per Share | |||||
| Basic EPS | CN¥0.44 | (CN¥0.75) | (CN¥1.20) | CN¥0.41 | CN¥0.68 |
| Diluted EPS | CN¥0.44 | (CN¥0.75) | (CN¥1.20) | CN¥0.41 | CN¥0.67 |
| Revenue Per Share | CN¥2.08 | CN¥2.06 | CN¥3.21 | CN¥5.54 | CN¥5.31 |
| Shares | |||||
| Basic Shares Outstanding | 451.7M | 451.7M | 451.7M | 451.7M | 429.4M |
| Diluted Shares Outstanding | 451.7M | 451.7M | 451.7M | 451.7M | 429.4M |
| Profitability Metrics | |||||
| EBITDA | — | (143.3M) | (163.1M) | 389.8M | 369.9M |
| D&A | — | 214.2M | 207.6M | 175.9M | 88.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026